Washington HB1425 mandates insurance coverage for pharmacogenomic testing for psychotropic medications without prior authorization or step therapy.

Washington HB1425 requires health carriers and Medicaid managed care organizations to cover pharmacogenetic testing for psychotropic medications, effective January 1, 2026. This testing, which analyzes a patient's genetic makeup to optimize medication effectiveness, must be supported by medical and scientific evidence. The bill prohibits prior authorization or step therapy requirements for this coverage.

Washington HB1425 mandates insurance coverage for pharmacogenomic testing for psychotropic medications without prior authorization or step therapy.

Washington HB1425 requires health carriers and Medicaid managed care organizations to cover pharmacogenetic testing for psychotropic medications, effective January 1, 2026. This testing, which analyzes a patient's genetic makeup to optimize medication effectiveness, must be supported by medical and scientific evidence. The bill prohibits prior authorization or step therapy requirements for this coverage.